JP2011507896A5 - - Google Patents

Download PDF

Info

Publication number
JP2011507896A5
JP2011507896A5 JP2010539862A JP2010539862A JP2011507896A5 JP 2011507896 A5 JP2011507896 A5 JP 2011507896A5 JP 2010539862 A JP2010539862 A JP 2010539862A JP 2010539862 A JP2010539862 A JP 2010539862A JP 2011507896 A5 JP2011507896 A5 JP 2011507896A5
Authority
JP
Japan
Prior art keywords
compound according
pyrrolo
phenylamino
pyrimidine
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010539862A
Other languages
English (en)
Japanese (ja)
Other versions
JP5710269B2 (ja
JP2011507896A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/087626 external-priority patent/WO2009082687A1/en
Publication of JP2011507896A publication Critical patent/JP2011507896A/ja
Publication of JP2011507896A5 publication Critical patent/JP2011507896A5/ja
Application granted granted Critical
Publication of JP5710269B2 publication Critical patent/JP5710269B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010539862A 2007-12-21 2008-12-19 アザインドリジン類と使用方法 Expired - Fee Related JP5710269B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1594207P 2007-12-21 2007-12-21
US61/015,942 2007-12-21
PCT/US2008/087626 WO2009082687A1 (en) 2007-12-21 2008-12-19 Azaindolizines and methods of use

Publications (3)

Publication Number Publication Date
JP2011507896A JP2011507896A (ja) 2011-03-10
JP2011507896A5 true JP2011507896A5 (enExample) 2012-01-19
JP5710269B2 JP5710269B2 (ja) 2015-04-30

Family

ID=40352017

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010539862A Expired - Fee Related JP5710269B2 (ja) 2007-12-21 2008-12-19 アザインドリジン類と使用方法

Country Status (12)

Country Link
US (1) US8486963B2 (enExample)
EP (1) EP2220092B1 (enExample)
JP (1) JP5710269B2 (enExample)
KR (1) KR20100099185A (enExample)
CN (1) CN101945875B (enExample)
AU (1) AU2008340247B2 (enExample)
BR (1) BRPI0819505A2 (enExample)
CA (1) CA2708176A1 (enExample)
ES (1) ES2387707T3 (enExample)
IL (1) IL206125A (enExample)
NZ (1) NZ586575A (enExample)
WO (1) WO2009082687A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102020651B (zh) 2010-11-02 2012-07-18 北京赛林泰医药技术有限公司 6-芳基氨基吡啶酮甲酰胺mek抑制剂
KR20130016041A (ko) * 2011-08-04 2013-02-14 재단법인 의약바이오컨버젼스연구단 신규한 아닐린 유도체 및 이의 용도
KR20130118612A (ko) * 2012-04-20 2013-10-30 (주)네오믹스 신규한 아미노피리딘 유도체 및 이의 용도
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
WO2015186769A1 (ja) * 2014-06-03 2015-12-10 株式会社ガイア環境技術研究所 食品、医薬品、化粧品及び飼料に利用される非晶質ケイ素、及びその製造方法、製造装置
AU2017249229A1 (en) 2016-04-15 2018-10-04 Genentech, Inc. Diagnostic and therapeutic methods for cancer
JP7212956B2 (ja) 2017-05-19 2023-01-26 エヌフレクション セラピューティクス インコーポレイテッド 皮膚障害の処置用のピロロピリジン-アニリン化合物
ES2913213T3 (es) 2017-05-19 2022-06-01 Nflection Therapeutics Inc Compuestos heteroaromáticos de anilina condensados para el tratamiento de trastornos dérmicos
KR102811888B1 (ko) 2017-09-08 2025-05-27 에프. 호프만-라 로슈 아게 암의 진단 및 치료 방법
US20210008047A1 (en) 2018-02-13 2021-01-14 Vib Vzw Targeting minimal residual disease in cancer with rxr antagonists
SG11202010679SA (en) 2018-05-17 2020-11-27 Bayer Ag Substituted dihydropyrazolo pyrazine carboxamide derivatives
EP3883552B1 (en) 2018-11-20 2025-04-09 NFlection Therapeutics, Inc. Cyanoaryl-aniline compounds for treatment of dermal disorders
WO2020106305A1 (en) 2018-11-20 2020-05-28 Nflection Therapeutics, Inc. Thienyl-aniline compounds for treatment of dermal disorders
CN113473986B (zh) 2018-11-20 2024-10-11 恩福莱克逊治疗有限公司 用于治疗皮肤疾病萘啶酮苯胺化合物
WO2021094210A1 (en) 2019-11-12 2021-05-20 Bayer Aktiengesellschaft Substituted pyrazine carboxamide derivatives as prostaglandin ep3 receptor antagonists
CN117157065A (zh) 2021-01-21 2023-12-01 恩福莱克逊治疗有限公司 吡咯并吡啶-苯胺化合物的晶型
US20260048075A1 (en) 2022-08-10 2026-02-19 Vib Vzw Inhibition of TCF4/ITF2 in the Treatment of Cancer
WO2026019990A1 (en) 2024-07-18 2026-01-22 Genentech, Inc. Methods of treating cancer with anti-ccr8/anti-cd3 bispecific antibodies

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU11248A1 (ru) 1927-03-29 1929-09-30 В.С. Григорьев Способ очистки антрацена
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
JPH08176070A (ja) 1994-12-19 1996-07-09 Mitsubishi Chem Corp ジデプシド誘導体及びpi3キナーゼ阻害剤
JPH08175990A (ja) 1994-12-19 1996-07-09 Mitsubishi Chem Corp Pi3キナーゼ阻害剤とその製造法
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
CA2218503C (en) 1995-04-20 2001-07-24 Pfizer Inc. Arylsulfonyl hydroxamic acid derivatives
GB9521987D0 (en) 1995-10-26 1996-01-03 Ludwig Inst Cancer Res Phosphoinositide 3-kinase modulators
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
DK0780386T3 (da) 1995-12-20 2003-02-03 Hoffmann La Roche Matrixmetalloproteaseinhibitorer
CA2242425C (en) 1996-02-13 2006-07-18 Zeneca Limited Quinazoline derivatives as vegf inhibitors
NZ331191A (en) 1996-03-05 2000-03-27 Zeneca Ltd 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
EP0818442A3 (en) 1996-07-12 1998-12-30 Pfizer Inc. Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor
EP0923585B1 (en) 1996-07-18 2002-05-08 Pfizer Inc. Phosphinate based inhibitors of matrix metalloproteases
EP0922030A1 (en) 1996-08-23 1999-06-16 Pfizer Inc. Arylsulfonylamino hydroxamic acid derivatives
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
US6077864A (en) 1997-01-06 2000-06-20 Pfizer Inc. Cyclic sulfone derivatives
HUP0000852A2 (hu) 1997-02-03 2001-05-28 Pfizer Products Inc. Aril-szulfonil-amino-hidroxámsav-származékok, valamint e vegyületeket tartalmazó gyógyászati készítmények
JP2000507975A (ja) 1997-02-07 2000-06-27 ファイザー・インク N−ヒドロキシ−β−スルホニルプロピオンアミド誘導体類及びそれらのマトリックスメタロプロテイナーゼ阻害薬としての使用
ES2284200T3 (es) 1997-02-12 2007-11-01 Electrophoretics Limited Marcadores proteicos para cancer de pulmon y uso de los mismos.
TR200000368T2 (tr) 1997-08-08 2000-07-21 Pfizer Products Inc. Ariloksiariarilsülfonilamino hidroksamik asit türevleri.
GB9725782D0 (en) 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
GB9801690D0 (en) 1998-01-27 1998-03-25 Pfizer Ltd Therapeutic agents
JP4462654B2 (ja) 1998-03-26 2010-05-12 ソニー株式会社 映像素材選択装置及び映像素材選択方法
PA8469401A1 (es) 1998-04-10 2000-05-24 Pfizer Prod Inc Derivados biciclicos del acido hidroxamico
PA8469501A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
EP1004578B1 (en) 1998-11-05 2004-02-25 Pfizer Products Inc. 5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives
EE05345B1 (et) 1999-02-10 2010-10-15 Astrazeneca Ab Kinasoliini derivaadid angiogeneesi inhibiitoritena
IL147150A0 (en) 1999-07-16 2002-08-14 Warner Lambert Co Method for treating chronic pain using mek inhibitors
PT1244647E (pt) 1999-11-05 2006-10-31 Astrazeneca Ab Derivados de quinazolina como inibidores de vegf
HRP20020751B1 (hr) 2000-02-15 2011-01-31 Sugen Pirolom supstituirani 2-indolinoni kao inhibitori protein kinaze
JP2001247477A (ja) 2000-03-03 2001-09-11 Teikoku Hormone Mfg Co Ltd 抗腫瘍剤
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
US6403588B1 (en) 2000-04-27 2002-06-11 Yamanouchi Pharmaceutical Co., Ltd. Imidazopyridine derivatives
AU7349801A (en) * 2000-07-19 2002-01-30 Warner Lambert Co Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
US7141576B2 (en) 2001-01-16 2006-11-28 Smithkline Beecham (Cork) Limited Cancer treatment method
US6605056B2 (en) 2001-07-11 2003-08-12 Scimed Life Systems, Inc. Conformable balloon
WO2003018057A1 (en) 2001-07-26 2003-03-06 Santen Pharmaceutical Co., Ltd. Remedy for glaucoma comprising as the active ingredient compound having pi3 kinase inhibitory effect
US6703414B2 (en) 2001-09-14 2004-03-09 Arizona Board Of Regents On Behalf Of The University Of Arizona Device and method for treating restenosis
CN100391958C (zh) 2001-09-19 2008-06-04 安万特医药股份有限公司 化合物
AU2002349912A1 (en) 2001-10-24 2003-05-06 Iconix Pharmaceuticals, Inc. Modulators of phosphoinositide 3-kinase
AU2002357667A1 (en) 2001-10-24 2003-05-06 Iconix Pharmaceuticals, Inc. Modulators of phosphoinositide 3-kinase
AU2002356871A1 (en) 2001-10-30 2003-05-12 Pharmacia Corporation Heteroaromatic carboxamide derivatives for the treatment of inflammation
SG2013013339A (en) 2002-03-13 2014-12-30 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
WO2003077855A2 (en) 2002-03-13 2003-09-25 Array Biopharma, Inc N3 alkylated benzimidazole derivatives as mek inhibitors
MXPA05000453A (es) 2002-07-10 2005-03-23 Applied Research Systems Derivados de benceno fusionados a azolidinona-vinilo.
US20040092561A1 (en) 2002-11-07 2004-05-13 Thomas Ruckle Azolidinone-vinyl fused -benzene derivatives
EP1531813A1 (en) 2002-07-10 2005-05-25 Applied Research Systems ARS Holding N.V. Use of compounds for increasing spermatozoa motility
WO2004017950A2 (en) 2002-08-22 2004-03-04 Piramed Limited Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
JP2004203748A (ja) * 2002-12-24 2004-07-22 Kissei Pharmaceut Co Ltd 新規なイミダゾ[1,2−c]ピリミジン誘導体、それを含有する医薬組成物およびそれらの用途
CA2528603A1 (en) * 2003-06-20 2004-12-29 Celltech R & D Limited Thienopyridone derivatives as kinase inhibitors
US20050049276A1 (en) 2003-07-23 2005-03-03 Warner-Lambert Company, Llc Imidazopyridines and triazolopyridines
US7419978B2 (en) * 2003-10-22 2008-09-02 Bristol-Myers Squibb Company Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors
KR101190912B1 (ko) * 2003-11-19 2012-10-12 어레이 바이오파마 인크. Mek의 헤테로시클릭 억제제 및 그의 사용 방법
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
GB0520657D0 (en) 2005-10-11 2005-11-16 Ludwig Inst Cancer Res Pharmaceutical compounds
GB0601962D0 (en) * 2006-01-31 2006-03-15 Ucb Sa Therapeutic agents
PE20081679A1 (es) 2006-12-07 2008-12-18 Hoffmann La Roche Compuestos del inhibidor de fosfoinositida 3-cinasa y metodos de uso

Similar Documents

Publication Publication Date Title
JP2009504763A5 (enExample)
JP2006182786A5 (enExample)
JP2011526924A5 (enExample)
JP2011526926A5 (enExample)
JP2013507415A5 (enExample)
JP2010077141A5 (enExample)
JP2011529070A5 (enExample)
JP2007522098A5 (enExample)
JP2011006480A5 (enExample)
JP2012500260A5 (enExample)
JP2006523216A5 (enExample)
JP2006524660A5 (enExample)
JP2013514980A5 (enExample)
JP2009524676A5 (enExample)
JP2017531038A5 (enExample)
JP2004516314A5 (enExample)
JP2009536660A5 (enExample)
GEP20105025B (en) Pharmaceutical compositions for treatent of atherosclerosis and related conditions and use thereof for treatment of these diseases
JP2006503850A5 (enExample)
HRP20211762T1 (hr) Derivati benzoksaborola za liječenje bakterijskih infekcija
JP2007536241A (ja) 糖尿病性腎症の処置のためのa2aアデノシンレセプターアゴニスト
JP2011505356A5 (enExample)
JP2008514718A5 (enExample)
JP2013518036A5 (enExample)
JP2011517697A5 (enExample)